6,513 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 6,513 shares of the company’s stock, valued at approximately $585,000.

A number of other large investors have also added to or reduced their stakes in AXSM. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Axsome Therapeutics in the second quarter valued at $27,000. EntryPoint Capital LLC purchased a new position in shares of Axsome Therapeutics in the 1st quarter worth $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Axsome Therapeutics in the 2nd quarter worth about $47,000. Russell Investments Group Ltd. raised its position in shares of Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after buying an additional 777 shares in the last quarter. Finally, Natixis lifted its holdings in shares of Axsome Therapeutics by 13.6% in the 1st quarter. Natixis now owns 1,235 shares of the company’s stock valued at $99,000 after acquiring an additional 148 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Up 0.5 %

Shares of NASDAQ AXSM opened at $98.68 on Friday. The stock has a 50 day moving average price of $90.99 and a 200 day moving average price of $85.01. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -15.11 and a beta of 1.26. Axsome Therapeutics, Inc. has a 52-week low of $60.28 and a 52-week high of $105.00. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the prior year, the company earned ($1.32) EPS. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on AXSM shares. Royal Bank of Canada boosted their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. UBS Group cut their target price on Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Finally, Wells Fargo & Company assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They issued an “overweight” rating and a $140.00 target price for the company. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.93.

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares in the company, valued at approximately $913,282.62. This trade represents a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.